DR. JOHN ALBERT LANG, MD
Osteopathic Medicine at Haworth Dr, Raleigh, NC

5985836, Nov 16, 1999

Jul 31, 1998

9/127574

Patrick D. Bastek - Chapel Hill NC
John M. Lang - Raleigh NC
George A. Baumbach - Knightdale NC
Ruben G. Carbonell - Raleigh NC

Bayer Corporation - Berkeley CA

A61K 3800, A61K 3802, C07K 500, C07K 700

514 17

Peptides which bind to alpha-1 Proteinase inhibitor (AlPI) are disclosed. The peptides have an available AlPI binding domain which may be any of the following preferred sequences: Val Ile Trp Leu Val Arg, Ile Ile Trp Leu Tyr Lys, Arg Tyr Arg Ile Phe Ile, Arg Ala Phe Trp Tyr Ile, Arg Phe Ile Tyr Tyr Thr, Tyr Lys Phe Arg Phe Trp, Leu Ile Val His Arg Trp, Pro Tyr Trp Ile Val Arg, Ala Arg Trp Tyr Ile His, Gln Tyr His Phe Trp Tyr, Arg Leu Trp Arg Tyr Gly, Val Ile Tyr Leu Val Arg, Val Ile Phe Leu Val Arg, Lys Ile Phe Leu Val Arg, Arg Ile Phe Leu Val Arg, His Ile Phe Leu Val Arg, Arg Val Leu Phe Ile Val, or Arg Val Leu Phe Ile His (SEQ ID NOS: 1-8, 10, 11, 15, 36, 37, 45, 46, 47, 61, and 62 respectively). A method of using peptides having these available binding domains in an affinity chromatography process to purify AlPI is described.

5786458, Jul 28, 1998

Jun 28, 1996

8/672255

George A. Baumbach - Knightdale NC
David J. Hammond - Raleigh NC
John M. Lang - Raleigh NC
Cynthia J. Galloway - Garner NC

Bayer Corporation - Berkeley CA

C07K 300

530412

A process for viral inactivation of a solution containing a biologically active protein, wherein the process comprises the steps of 1) contacting the solution with an immobilized ligand under conditions which allow protein to bind to the ligand, 2) subjecting the bound protein to a viral inactivation method under conditions which would result in substantial denaturation of the protein if it were not bound to the ligand, and 3) recovering the protein by washing the immobilized protein under conditions which favor the release of the protein into the solution under conditions in which the recovered protein retains its biological activity.